Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

ALN OATF Vena Cava Filter

NCT: NCT05785676 · COMPLETED

NCT IDNCT05785676
StatusCOMPLETED
Start Date2023-02-14
Completion2025-07-31

Brief Summary

Migration of a thrombus in the pulmonary circulation is the leading cause of pulmonary embolism (PE). It can be prevented mechanically by implanting a vena cava filter (VCF) in the inferior vena cava. The implation of a VCF is indicated for patients with acute PE and a contraindication to anticoagulation, with an acute deep vein thrombosis (DVT) without PE and a contraindication to anticoagulation or with acute venous thromboembolism (less than 3 months) in whom an interventional gesture at hemorrhagic and thromboembolic risk contraindicates anticoagulation. The purpose of this study is to describe the rates of implantation, removal and complications associated with the use of the optional ALN OATF VCF in current practice.

Frequently Asked Questions

What is ALN OATF Vena Cava Filter?

ALN OATF Vena Cava Filter is a clinical trial registered under NCT05785676. Current status: COMPLETED.

What is the status of NCT05785676?

The current status of NCT05785676 (ALN OATF Vena Cava Filter) is: COMPLETED.

When did ALN OATF Vena Cava Filter start?

ALN OATF Vena Cava Filter started on 2023-02-14.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.